Division of Allergy, Asthma, and Rheumatology, Department of Paediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan
School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan.
BMJ. 2023 Aug 2;382:e075835. doi: 10.1136/bmj-2023-075835.
To investigate the associations between exposure to antenatal corticosteroids and serious infection in children during the first three, six, and 12 months of life.
Nationwide cohort study.
National Health Insurance Research Database, Birth Reporting Database, and Maternal and Child Health Database, 1 January 2008 to 31 December 2019, to identify all pregnant individuals and their offspring in Taiwan.
1 960 545 pairs of pregnant individuals and their singleton offspring. 45 232 children were exposed and 1 915 313 were not exposed to antenatal corticosteroids.
Incidence rates were estimated for overall serious infection, sepsis, pneumonia, acute gastroenteritis, pyelonephritis, meningitis or encephalitis, cellulitis or soft tissue infection, septic arthritis or osteomyelitis, and endocarditis during the first three, six, and 12 months of life in children exposed versus those not exposed to antenatal corticosteroids. Cox proportional hazards models were performed to quantify adjusted hazard ratios with 95% confidence intervals for each study outcome.
The study cohort was 1 960 545 singleton children: 45 232 children were exposed to one course of antenatal corticosteroids and 1 915 313 children were not exposed to antenatal corticosteroids. The adjusted hazard ratios for overall serious infection, sepsis, pneumonia, and acute gastroenteritis among children exposed to antenatal corticosteroids were significantly higher than those not exposed to antenatal corticosteroids during the first six months of life (adjusted hazard ratio 1.32, 95% confidence interval 1.18 to 1.47, P<0.001, for overall serious infection; 1.74, 1.16 to 2.61, P=0.01, for sepsis; 1.39, 1.17 to 1.65, P<0.001, for pneumonia; and 1.35, 1.10 to 1.65, P<0.001, for acute gastroenteritis).Similarly, the adjusted hazard ratios for overall serious infection (P<0.001), sepsis (P=0.02), pneumonia (P<0.001), and acute gastroenteritis (P<0.001) were significantly higher from birth to 12 months of life. In the sibling matched cohort, the results were comparable with those observed in the whole cohort, with a significantly increased risk of sepsis in the first six (P=0.01) and 12 (P=0.04) months of life.
This nationwide cohort study found that children exposed to one course of antenatal corticosteroids were significantly more likely to have an increased risk of serious infection during the first 12 months of life. These findings suggest that before starting treatment, the long term risks of rare but serious infection associated with antenatal corticosteroids should be carefully weighed against the benefits in the perinatal period.
研究产前皮质类固醇暴露与儿童生命前 3 个月、6 个月和 12 个月期间严重感染之间的关系。
全国性队列研究。
国家健康保险研究数据库、出生报告数据库和母婴健康数据库,2008 年 1 月 1 日至 2019 年 12 月 31 日,以确定台湾所有孕妇及其子女。
1960545 对孕妇及其单胎子女。45232 名儿童暴露于产前皮质类固醇,1915313 名儿童未暴露于产前皮质类固醇。
估计儿童生命前 3 个月、6 个月和 12 个月期间总体严重感染、败血症、肺炎、急性肠胃炎、肾盂肾炎、脑膜炎或脑炎、蜂窝织炎或软组织感染、脓毒性关节炎或骨髓炎和心内膜炎的发生率,比较暴露于和未暴露于产前皮质类固醇的儿童。采用 Cox 比例风险模型对每种研究结果的调整后危险比进行量化,置信区间为 95%。
研究队列为 1960545 名单胎儿童:45232 名儿童接受了 1 个疗程的产前皮质类固醇治疗,1915313 名儿童未接受产前皮质类固醇治疗。与未暴露于产前皮质类固醇的儿童相比,暴露于产前皮质类固醇的儿童在前 6 个月生命期的总体严重感染、败血症、肺炎和急性肠胃炎的调整后危险比显著更高(调整后危险比 1.32,95%置信区间 1.18 至 1.47,P<0.001,用于总体严重感染;1.74,1.16 至 2.61,P=0.01,用于败血症;1.39,1.17 至 1.65,P<0.001,用于肺炎;1.35,1.10 至 1.65,P<0.001,用于急性肠胃炎)。同样,从出生到 12 个月生命期的总体严重感染(P<0.001)、败血症(P=0.02)、肺炎(P<0.001)和急性肠胃炎(P<0.001)的调整后危险比也显著更高。在同胞匹配队列中,结果与整个队列观察到的结果相当,在前 6 个月(P=0.01)和 12 个月(P=0.04)生命期内,败血症的风险显著增加。
这项全国性队列研究发现,接受 1 个疗程产前皮质类固醇治疗的儿童在生命的前 12 个月内严重感染的风险显著增加。这些发现表明,在开始治疗之前,应仔细权衡产前皮质类固醇相关罕见但严重感染的长期风险与围产期的益处。